The role of insulin detemir in overweight type 2 diabetes management

References

• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitusN Eng J Med1993329977986
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow up of intensive glucose control in type 2 diabetesN Engl J Med20083591577158918784090
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetesDiabetes Care200831Suppl 1S12S5418165335
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation (IDF) Task Force on Clinical Practice Guidelines. Global guideline for type 2 diabetes. Available at http://www.idf.org/home/index.cfm?node=1449 Accessed March 09, 2009.
   Google Scholar
• FoxKMGerberRABolinderBChenJKumarSPrevalence of inadequate glycaemic control among patients with type 2 diabetes in the United Kingdom general practise research database: a series of retrospective analyses of data from 1998 through 2002Clin Ther20062838839516750453
   PubMed Web of Science ®Google Scholar
• BoSCavallo-PerinPGentileLRelationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitusActa Diabetol20003712512911277312
   PubMedGoogle Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2006291963197216873813
   PubMed Web of Science ®Google Scholar
• NorrisSLZhangXAvenellALong term effectiveness of lifestyle and behavioural weight loss interventions in adults with type 2 diabetes: a meta-analysisAm J Med200411776277415541326
   PubMed Web of Science ®Google Scholar
• HaffnerSMD’AgostinoRJrMykkanenLInsulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors. the Insulin Resistance Atherosclerosis StudyDiabetes Care19992256256810189532
   PubMed Web of Science ®Google Scholar
• GottesmanIManaging obesity and glycemic control in insulin-using patients: clinical relevance and practise recommendationsDiabetes Res Clin Pract200465SupplS17S2215315866
   PubMedGoogle Scholar
• SinhaAFormicaCTsalamandrisCEffects of insulin in body composition in patients with insulin-dependent and non-insulin dependent diabetesDiabet Med19961340468741811
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHRyysyLKauppilaMEffect of obesity on the response to insulin therapy in non-insulin dependent diabetes mellitusJ Clin Endocrinol Metab199782403740439398709
   PubMed Web of Science ®Google Scholar
• PetersALThe clinical implications of insulin resistanceAm J Manag Care2000613 SupplS668S67411183420
   PubMedGoogle Scholar
• HellerSWeight gain during insulin therapy in patients with type 2 diabetes mellitusDiabetes Res Clin Pract200465SupplS23S2715315867
   PubMedGoogle Scholar
• SnoekFJBarriers to good glycaemic control: the patient’s perspectiveInt J Obes Relat Metab Disord200024Suppl 3S12S2011063280
   PubMedGoogle Scholar
• PurnellJQWeyerCWeight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesityTreat Endocrinol20032334715871553
   PubMedGoogle Scholar
• PingetMJeandidierNLong-term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumpsHorm Metab Res1998304754869761375
   PubMedGoogle Scholar
• MakimattilaSNikkilaKYki-JarvinenHCauses of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitusDiabetologia19994240641210230643
   PubMed Web of Science ®Google Scholar
• GoudswaardANFurlongNJRuttenGEInsulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitusCochrane Database Sys Rev4CD003418
   Google Scholar
• GaedePVedelPLarsenNMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Eng J Med2003348383393
   PubMed Web of Science ®Google Scholar
• WhittinghamJLHavelundSJonassenLCrystal structure of a prolonged-acting insulin with albumin binding propertiesBiochemistry199736282628319062110
   PubMed Web of Science ®Google Scholar
• KurtzhasPHavelundSJonassenIAlbumin binding and time-action of acylated insulin in various speciesJ Pharm Sci1996853043088699334
   PubMedGoogle Scholar
• SoranHYounisNInsulin detemir: a new basal insulin analogueDiabetes Obes Metab20068263016367879
   PubMed Web of Science ®Google Scholar
• PieberTRPlankJGeorzerEDuration of action, pharmacodynamci profile and between-subject variability of insulin detemir in subjects with type 1 diabetesDiabetes200251Suppl 2A214
   Google Scholar
• The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetesActa Diabetol20084525326818766296
   PubMed Web of Science ®Google Scholar
• HermansenKDaviesMDoes insulin detemir have a role in reducing risk of insulin-associated weight gainDiabetes Obes Metab2007920921717391147
   PubMed Web of Science ®Google Scholar
• BushMAIntensive diabetes therapy and body weight: focus on insulin detemirEndocrinol Metab Clin North Am200736Suppl 1334417881330
   PubMed Web of Science ®Google Scholar
• HomePBartleyPRussel-JonesDInsulin detemir offers improved glycaemic control compared to NPH insulin in people with type 1 diabetes: a randomised clinical trialDiabetes Care2004271081108715111525
   PubMed Web of Science ®Google Scholar
• PiberTRTreichelH-CRobertsonLIInsulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetesDiabetologia200548A92
   Google Scholar
• Russel-JonesDSimpsonRHyellebergBEffects of QD insulin detemir or neutral protamine Hagedron on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimenClin Ther20042672473615220016
   PubMedGoogle Scholar
• HermansenKFontainePKukoljaKKInsulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetesDiabetologia20044762262915298338
   PubMed Web of Science ®Google Scholar
• KolendorfKRossGPPavlic-RenarIInsulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetesDiabet Med20062372973516842476
   PubMed Web of Science ®Google Scholar
• RobertsonKJSchonleEGucevZInsulin detemir compared with NPH insulin in children and adolescents with type 1 diabetesDiabet Med200724273417227321
   PubMed Web of Science ®Google Scholar
• RaslovaKBogoevMRazIInsulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetesDiabetes Res Clin Pract20046619320115533587
   PubMed Web of Science ®Google Scholar
• HaakTTiengoADraegerESuntumMWaldhausWLower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetesDiabetes Obes Metab20057566415642076
   PubMed Web of Science ®Google Scholar
• HermansenKDaviesMDerezinskiTA 26 week, randomized, parallel, treat to target trail comparing insulin detemir with NPH insulin ass add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetesDiabetes Care2006291269127416732007
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasACharpentierGClausonPComparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetesClin Ther2006281569158117157113
   PubMed Web of Science ®Google Scholar
• RosenstockJDaviesMHomePDA randomized treat to target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose lowering drugs in insulin-naïve people with type 2 diabetesDiabetologia20085140841618204830
   PubMed Web of Science ®Google Scholar
• KingABOnce-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover studyDiabetes Obes Metab200911697119120433
   PubMed Web of Science ®Google Scholar
• HeiseTPieberTRTowards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes Obes Metab2007964865917645556
   PubMed Web of Science ®Google Scholar
• HeinemannLVariability of insulin absorption and insulin actionDiabetes Technol Ther2002467368212450450
   PubMedGoogle Scholar
• Russell-JonesDInsulin detemir: improving the predictability of glycaemic controlInt J Obes Relat Metab Disord200428S29S3415306835
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLRonnBBLower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesDiabetes2004531614162015161770
   PubMed Web of Science ®Google Scholar
• KleinOLyngeJEndahlLAlbumin bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetesDiabetes Obes Metab2007929029917391154
   PubMed Web of Science ®Google Scholar
• HollanderPCooperJBregnhøjJA 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesClin Ther2008301976198719108786
   PubMed Web of Science ®Google Scholar
• LüddekeHJSreenanSAczelSPREDICTIVE Study GroupPREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohortDiabetes Obes Metab2007942843417391171
   PubMed Web of Science ®Google Scholar
• MeneghiniLFRosenbergKHKoenenCInsulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE studyDiabetes Obes Metab2007941842717391170
   PubMed Web of Science ®Google Scholar
• HermansenKLundPClemmensenKon behalf of the Danish PREDICTIVE study3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study groupRev Diabet Stud20074899717823693
   PubMedGoogle Scholar
• YenigunMHonkaMSwitching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE studyInt J Clin Pract20096342543219222627
   PubMed Web of Science ®Google Scholar
• DornhorstALüddekeHJSreenanSPREDICTIVE StudyInsulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE studyInt J Clin Pract20086265966518324957
   PubMed Web of Science ®Google Scholar